Resumen
Rat sarcoma virus (RAS) GTP-ase proteins represent a key element in cellular proliferation, growth, and differentiation. Three different isoforms of RAS proteins have been identified to date (KRAS, NRAS, HRAS) and mutations in KRAS are frequently found in human cancers, among which the Non-Small Cell Lung Cancer (NSCLC). In this review we assess molecular, prognostic, and clinico-pathological characteristics of KRAS mutations in NSCLC patients. Next, we present current therapeutic strategies for KRAS mutant NSCLC patients and mechanisms of acquired resistance identified to date. We then focus on the role of immune-checkpoint inhibitors in KRAS mutant NSCLC patients. Finally, we will overview ongoing trials and future needs for this subpopulation cohort.